Powering Up Your Oncology Patient Support Program

Posted by Rachael Pius on Nov 20, 2019 8:00:00 AM

Gila Allswang co-wrote this blog post with Rachael Pius.

As oncology patients and caregivers continue to play a more active role in their healthcare decisions and have more options available to them than ever before, many pharma companies are upping their investment in patient support programs. While patient-centered care can empower and engage patients by building their knowledge—and can often drive competitive differentiation—it’s also fraught with its own challenge: Oncology patients simply are not aware of the service offerings provided by manufacturers and are much less likely to use them. On average, only 46% of oncology patients and caregivers are aware of the offerings available to them, according to ZS’s recent survey on patient support programs. In many cases they may also find the offerings from other stakeholders in the health ecosystem to be more relevant to meet their needs. Further, oncology patients are offered support from many different players across the healthcare ecosystem—patient advocacy, specialty pharmacy, payers, hospital systems and pharmaceutical manufacturers are all offering patients support. There’s a high degree of overlap across the landscape, so it’s important for manufacturers to understand where patients are accessing support and why.


>
Read More

Accelerating Real-World Evidence to Advance the Trial Landscape

Posted by Maria Whitman on Jul 19, 2017 9:42:04 AM

Mimi Traylor-Knowles co-wrote this blog post with Maria Whitman.

At the 2017 Annual Society of Clinical Oncology Annual Meeting (ASCO), Dr. Sean Khozin, senior medical officer at the FDA, opened his Saturday session with some trivia: When was the first controlled clinical trial? The answer, which surprised many of my fellow attendees, was 1747, when James Lind held a trial to determine if citrus juice would help control the symptoms of scurvy. Dr. Khozin then showed a timeline to demonstrate the history of controlled clinical trials. He concluded his session with a single but poignant visual: a flat line stretching more than 250 years from then until now. As the world has made historic progress in innovation—from steam locomotives to a man on the moon to the internet and all that we have today—controlled clinical trials have remained largely the same. 


>
Read More

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

Posted by Maria Whitman on Jul 13, 2017 10:59:32 AM

Mimi Traylor-Knowles co-wrote this blog post with Maria Whitman.

Thomas Edison said: “There is a way to do it better. Find it.” Real-world evidence is a tool to help us do just that.

The theme at this year’s American Society of Clinical Oncology (ASCO) 2017 Annual Meeting (ASCO) was "Making a Difference in Cancer Care With YOU," which highlights the importance of everyone's involvement in improving care for patients with cancer. This theme also reminds us that improving care is part innovation and part application of what we have to do better.


>
Read More

Real-World Evidence as a Mechanism for Patient-Centric and Individualized Care

Posted by Maria Whitman on Jul 10, 2017 2:31:47 PM

Mimi Traylor-Knowles contributed to this blog post.

Recently, I sat in the audience of an oncology congress and heard a patient survivor and advocate describe critical transitions in his experience living with cancer: At diagnosis, he went from a “person” to a “patient,” and during clinical trial enrollment, he went from a “patient” to a “subject.” 


>
Read More